Alnylam Pharmaceuticals is a biopharmaceutical company focused on inventing and marketing therapeutics to cure several genetic disorders based on RNA interference. The company aims to offer treatment for neurological, cardiovascular, hepatic infectious diseases, and rare bleeding disorders. In collaboration with multiple partners, including Regeneron Pharmaceuticals, Sanofi Genzyme, and Vir Biotechnology, Alnylam is researching to introduce more innovative therapeutic products.